Enanta Pharmaceuticals (ENTA) Free Cash Flow (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Free Cash Flow data on file, last reported at -$7.2 million in Q1 2026.

• Quarterly Free Cash Flow rose 67.97% year-over-year to -$7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (up 104.95% YoY) and the FY2025 annual result came in at -$19.3 million, up 77.16% from the prior year.
• Free Cash Flow rose to -$7.2 million in Q1 2026, from -$11.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $17.4 million in Q2 2025 to a low of -$38.2 million in Q2 2023.
• A 5-year average of -$17.6 million and a median of -$17.2 million in 2022 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 462.82% — and 2025, when it soared 253.75%.
• Tracing ENTA's Free Cash Flow over 5 years: stood at -$35.6 million in 2022, then rose by 28.56% to -$25.5 million in 2023, then rose by 24.5% to -$19.2 million in 2024, then surged by 39.16% to -$11.7 million in 2025, then surged by 38.83% to -$7.2 million in 2026.
• The last three Free Cash Flow figures came in at -$7.2 million (Q1 2026), -$11.7 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.